Kusta (Lepra)

01Pathophysiology

Mycobacterium leprae is an obligate intracellular acid-fast bacillus that uniquely targets Schwann cells of peripheral nerves and macrophages in cool body regions. It has the longest doubling time of any known human pathogen, approximately 12 to 14 days, which explains the extremely long incubation period of 2 to 5 years (sometimes up to 20 years). The bacterium cannot be grown on artificial culture media, a fact frequently tested and often used as a distractor against other mycobacterial infections.

The clinical spectrum of leprosy is determined entirely by the host's cell-mediated immune (CMI) response, not by the virulence of the organism itself. This is the single most important concept for understanding leprosy on an exam.

At one pole, patients with a strong CMI response develop tuberculoid leprosy (TT). Their immune system effectively contains the bacilli, resulting in few, well-defined skin lesions with granuloma formation. However, this vigorous immune response also causes significant nerve damage early, because the immune attack on infected Schwann cells destroys the nerve. This is why tuberculoid patients have few bacilli but prominent neuropathy.

At the opposite pole, patients with a weak or absent CMI response develop lepromatous leprosy (LL). The immune system fails to contain the organism, allowing uncontrolled bacterial proliferation throughout the skin, nerves, nasal mucosa, eyes, and testes. This produces numerous, poorly defined, symmetric lesions with a very high bacterial load. Despite the enormous number of organisms, nerve damage in LL tends to be more gradual and diffuse ("glove-and-stocking" pattern) because the destructive granulomatous response is absent.

The bacterium's preference for cool body regions (skin, earlobes, nose, fingers, toes, anterior eye, testes) explains several classic findings: saddle nose deformity (nasal cartilage destruction), madarosis (loss of lateral eyebrows), testicular atrophy and gynecomastia, and the characteristic distribution of skin lesions on cooler extremities while sparing warmer areas like the axillae and groin.

Peripheral nerve involvement follows a predictable pattern. The nerves most commonly affected are those that run superficially through cool areas: the great auricular nerve (visible and palpable in the neck), the ulnar nerve (at the elbow), the median nerve (at the wrist), the common peroneal nerve (at the fibular head), and the posterior tibial nerve (behind the medial malleolus). Damage to these nerves produces the classic deformities: claw hand (ulnar nerve), wrist drop (radial nerve), foot drop (common peroneal nerve), and lagophthalmos (facial nerve).

02Classification and Clinical Manifestation

WHO Operational Classification

Ridley-Jopling Spectrum

Lepra Reactions (Immunologic Complications)

03Diagnostic Workup

The diagnosis of leprosy is fundamentally clinical. The WHO has established three cardinal signs, and the presence of any one of them is sufficient to establish the diagnosis in an endemic setting. These signs are: (1) a hypopigmented or reddish skin patch with definite loss of sensation, (2) a thickened peripheral nerve, and (3) acid-fast bacilli on slit-skin smear.

The slit-skin smear is performed by making a small incision in the skin (typically from the earlobes, elbows, knees, and active lesion margins), scraping dermal tissue, and staining with modified Ziehl-Neelsen stain. The result is reported as a Bacterial Index (BI), graded from 0 (no bacilli in 100 oil-immersion fields) to 6+ (more than 1000 bacilli per field). A positive smear automatically classifies the patient as multibacillary. However, a negative smear does not exclude leprosy, as paucibacillary patients often have a BI of zero.

The most accurate test is a full-thickness skin biopsy stained with Fite-Faraco stain (a modified acid-fast stain that is gentler than standard Ziehl-Neelsen, preserving the waxy M. leprae cell wall). Histopathology reveals the characteristic granulomatous pattern and, critically, demonstrates nerve involvement within the dermis, which is virtually pathognomonic for leprosy.

A frequently tested point: the lepromin test (Mitsuda reaction) is not a diagnostic test. It does not indicate current or past infection. It measures the patient's CMI response to M. leprae antigens and is used for classification and prognosis. A positive result (induration at 3 to 4 weeks) indicates intact CMI, seen in tuberculoid forms. A negative result indicates anergy, seen in lepromatous forms.

Another critical exam point: M. leprae cannot be cultured in vitro on any artificial media. The only laboratory growth models are the mouse footpad (Shepard's method) and the nine-banded armadillo, both used for research purposes. If a vignette describes successful culture of an acid-fast organism from a skin lesion, the answer is NOT leprosy.

04Management and Treatment

WHO Multidrug Therapy (MDT) Regimen

Management of Lepra Reactions

MDT is the cornerstone of leprosy treatment and must always include multiple drugs to prevent resistance. The rationale mirrors tuberculosis therapy: rifampicin is the most potent bactericidal agent, dapsone provides sustained bacteriostatic coverage, and clofazimine adds both bacteriostatic and anti-inflammatory properties (particularly useful in MB disease where ENL reactions may occur).

Rifampicin is given only once monthly under supervision because of its potent bactericidal activity (kills 99.9% of viable M. leprae in a single dose) and to ensure compliance. It is the single most important drug in the regimen.

Dapsone (diaminodiphenyl sulfone) is a folate synthesis inhibitor given daily. Key side effects to know for exams include hemolytic anemia (especially in G6PD-deficient patients, which must be screened before starting), methemoglobinemia, dapsone hypersensitivity syndrome (fever, rash, hepatitis within 6 weeks of starting), and rarely agranulocytosis.

Clofazimine is a riminophenazine dye with both antimycobacterial and anti-inflammatory properties. Its most notable side effect is reddish-brown to violet skin discoloration and ichthyosis (dry, scaly skin), which are reversible after stopping the drug. This cosmetic side effect is a common source of non-compliance and a frequent exam question.

A critical rule: MDT must never be stopped during lepra reactions. Reactions are immunologic events, not treatment failures. Treatment of reactions (corticosteroids or thalidomide) is given alongside continued MDT.

For thalidomide in ENL: it is the most effective agent available, but its use carries an absolute contraindication in women of childbearing potential unless strict pregnancy prevention programs are in place. If thalidomide is contraindicated, corticosteroids are the alternative. Clofazimine at higher doses (300 mg/day) can be used as a steroid-sparing agent for recurrent ENL.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on leprosy questions is by confusing the two poles of the disease spectrum. The intuitive assumption is that the more severe-looking form (lepromatous, with widespread lesions and high bacterial load) must have the strongest immune response. In reality, it is the opposite: lepromatous leprosy reflects immune failure, while tuberculoid leprosy reflects a robust immune response that limits bacterial growth but paradoxically causes more nerve damage per lesion.

A second frequent trap involves lepra reactions. Students often misinterpret a reaction as treatment failure or drug resistance and select "change antibiotics" or "stop MDT" as the answer. The correct response is always to continue MDT and treat the reaction separately. Furthermore, the distinction between Type 1 and Type 2 reactions hinges on a clean differentiator: Type 1 reactions cause worsening of existing old lesions, while Type 2 (ENL) produces new nodules on previously normal skin. If the vignette describes "new tender subcutaneous nodules with fever" in an MB patient on treatment, that is ENL, and the answer is thalidomide (or corticosteroids if the patient is a woman of childbearing age).

A third trap is the lepromin test. Students who see "skin test" in the context of mycobacterial disease reflexively equate it with a diagnostic tool (like the tuberculin skin test for TB). The lepromin test is not diagnostic. It does not tell you whether the patient has leprosy; it tells you what type of immune response the patient mounts. It is a prognostic and classification tool only.

Finally, any vignette that mentions successful culture of the organism on laboratory media is steering you away from leprosy. M. leprae is one of the very few human pathogens that absolutely cannot be grown in vitro. If culture is positive, consider atypical mycobacteria (M. marinum, M. ulcerans) or other diagnoses entirely.

The core competency being tested in leprosy questions is pattern recognition of the anesthetic hypopigmented patch with peripheral nerve thickening as the unifying finding, combined with understanding the immunologic spectrum that determines disease classification, prognosis, and treatment regimen selection.